WallStSmart

AtriCure Inc (ATRC)vsBecton Dickinson and Company (BDX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Becton Dickinson and Company generates 3925% more annual revenue ($22.23B vs $552.16M). BDX leads profitability with a 5.1% profit margin vs -0.8%. BDX appears more attractively valued with a PEG of 1.11. BDX earns a higher WallStSmart Score of 65/100 (B-).

ATRC

Hold

37

out of 100

Grade: F

Growth: 6.0Profit: 2.5Value: 5.7Quality: 8.5
Piotroski: 5/9Altman Z: 2.17

BDX

Strong Buy

65

out of 100

Grade: B-

Growth: 6.0Profit: 5.0Value: 6.0Quality: 5.0
Piotroski: 6/9Altman Z: 1.49
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ATRCUndervalued (+55.5%)

Margin of Safety

+55.5%

Fair Value

$73.91

Current Price

$27.10

$46.81 discount

UndervaluedFair: $73.91Overvalued
BDXUndervalued (+9.9%)

Margin of Safety

+9.9%

Fair Value

$200.45

Current Price

$151.16

$49.29 discount

UndervaluedFair: $200.45Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ATRC2 strengths · Avg: 8.5/10
Debt/EquityHealth
0.159/10

Conservative balance sheet, low leverage

Price/BookValuation
2.8x8/10

Reasonable price relative to book value

BDX2 strengths · Avg: 8.0/10
Price/BookValuation
1.7x8/10

Reasonable price relative to book value

EPS GrowthGrowth
28.6%8/10

Earnings expanding 28.6% YoY

Areas to Watch

ATRC4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.46B3/10

Smaller company, higher risk/reward

Operating MarginProfitability
0.4%3/10

Operating margin of 0.4%

PEG RatioValuation
10.002/10

Expensive relative to growth rate

BDX4 concerns · Avg: 3.0/10
P/E RatioValuation
25.2x4/10

Moderate valuation

Return on EquityProfitability
4.7%3/10

ROE of 4.7% — below average capital efficiency

Profit MarginProfitability
5.1%3/10

5.1% margin — thin

Altman Z-ScoreHealth
1.492/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : ATRC

The strongest argument for ATRC centers on Debt/Equity, Price/Book. Revenue growth of 14.3% demonstrates continued momentum.

Bull Case : BDX

The strongest argument for BDX centers on Price/Book, EPS Growth. PEG of 1.11 suggests the stock is reasonably priced for its growth.

Bear Case : ATRC

The primary concerns for ATRC are EPS Growth, Market Cap, Operating Margin.

Bear Case : BDX

The primary concerns for BDX are P/E Ratio, Return on Equity, Profit Margin.

Key Dynamics to Monitor

ATRC profiles as a turnaround stock while BDX is a value play — different risk/reward profiles.

ATRC carries more volatility with a beta of 1.26 — expect wider price swings.

ATRC is growing revenue faster at 14.3% — sustainability is the question.

BDX generates stronger free cash flow (546M), providing more financial flexibility.

Bottom Line

BDX scores higher overall (65/100 vs 37/100). ATRC offers better value entry with a 55.5% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AtriCure Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States, Europe, Asia, and internationally. The company is headquartered in Mason, Ohio.

Becton Dickinson and Company

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.

Visit Website →

Want to dig deeper into these stocks?